GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2 | decreases expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein | PMID:16022909 PMID:16446371 PMID:17156654 PMID:17327374 PMID:18928586 PMID:20383943 | Bcl2 | increases cleavage | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Bortezomib results in increased cleavage of BCL2 protein modified form | PMID:16118318 | Bcl2 | increases expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein | PMID:17895889 PMID:20051518 | Bcl2 | multiple interactions | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] | PMID:15173093 PMID:15781649 PMID:16118318 PMID:17326159 PMID:17351739 PMID:18718063 PMID:20471514 PMID:21302442 PMID:24377552 | |
Go Back to source page | Continue to Ontology report |